Amgen Unusual Options Activity
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
10 Health Care Stocks With Whale Alerts In Today's Session
These Three ETFs Look Ready for Breakout Moves, Roth MKM Says
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $74 Price Target
Gilead Sciences Analyst Ratings
Sector Update: Health Care Stocks Mixed Premarket Monday
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $150 Price Target
Alnylam Pharmaceuticals Analyst Ratings
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Key US Jobs Reports
"Interest rate cuts + Trump's return" two major expectations continue to ferment! Will this benefiting sector see the dawn?
Market participants believe that in recent three years, the biotechnology sector has been underperforming the broader market. Once the expectation of interest rate cuts is raised by the Fed, biotechnology companies, represented by innovative drugs, will have the ability to make up ground.
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio?
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space
5 Analysts Assess IQVIA Hldgs: What You Need To Know
Why Are Carisma Therapeutics Shares Surging Friday?
What's Going On With Moderna Stock Friday?
IQVIA Hldgs Analyst Ratings